Skip to content

Dyne Therapeutics, Inc. DYN Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Scholar Rock logo
Scholar RockSRRK
-$3K
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$160K
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$3K+25.0%
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.35B+153%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s gain/loss on asset sales?
Dyne Therapeutics, Inc. (DYN) reported gain/loss on asset sales of -$30K in Q1 2026.
How has Dyne Therapeutics, Inc.'s gain/loss on asset sales changed year-over-year?
Dyne Therapeutics, Inc.'s gain/loss on asset sales increased by 68.4% year-over-year, from -$95K to -$30K.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.